Autopsy report · NCT00918658
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
Cause of deathStaffing, sites or logistics
“PI closed lab”
Life of this trial
- Registered 1 year 2 months after it had already started.
- Ran for about 2 years 11 months before it stopped.
- 34 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Leukemia; Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- biologic sample preservation procedure; immunologic technique; laboratory biomarker analysis
- Participants
- 34
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
“PI retired, study closed” - Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing
“The PI closed this study and went to another institution.” - Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling
“Delivery of equipment. PI not had any further interaction with the company so closed study.” - Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation
“PI no longer at this facility” - Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
“Closed at PI's Request”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.